Disease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study

Basit Öğe Kaydı
dc.authoridGONEN, MUSTAFA SAIT/0000-0002-1089-623X
dc.authoridUysal, Serhat/0000-0002-0507-6966
dc.authoridCatak, Merve/0000-0003-2654-3911
dc.authoridCelik, Mehmet/0000-0001-7364-370X
dc.authoridTuna, Mazhar Muslum/0000-0001-5975-7786
dc.contributor.authorZuhur, Sayid Shafi
dc.contributor.authorOzturk, Beyza Olcay
dc.contributor.authorKeskin, Umran
dc.contributor.authorUysal, Serhat
dc.contributor.authorHacioglu, Aysa
dc.contributor.authorAvci, Ugur
dc.contributor.authorKarsli, Seda
dc.date.accessioned2024-10-29T17:58:21Z
dc.date.available2024-10-29T17:58:21Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractPurpose Despite several factors that may have been associated with poor disease-free survival (DFS) in patients with medullary thyroid carcinoma (MTC), only a few studies have evaluated the prognostic factors affecting DFS in MTC patients. Therefore, this study evaluated the prognostic factors affecting DFS, in a large number of patients with MTC. Methods Patients treated for MTC were retrospectively analyzed. Patients were stratified as having persistent/recurrent disease and no evidence of disease (NOD) at the last follow-up. The factors affecting DFS after the initial therapy and during the follow-up period were investigated. Results This study comprised 257 patients [females 160 (62.3%), hereditary disease 48 (18.7%), with a mean follow-up time of 66.8 +/- 48.5 months]. Persistent/recurrent disease and NOD were observed in 131 (51%) and 126 (49%) patients, respectively. In multivariate analysis, age > 55 (HR: 1.65, p = 0.033), distant metastasis (HR: 2.41, p = 0.035), CTN doubling time (HR: 2.7, p = 0.031), and stage III vs. stage II disease (HR 3.02, p = 0.048) were independent predictors of persistent/recurrent disease. Although 9 (8%) patients with an excellent response after the initial therapy experienced a structural recurrence, the absence of an excellent response was the strongest predictor of persistent/recurrent disease (HR: 5.74, p < 0.001). Conclusions The absence of an excellent response after initial therapy is the strongest predictor of a worse DFS. However, a significant proportion of patients who achieve an excellent response could experience a structural recurrence. Therefore, careful follow-up of patients, including those achieving an excellent response is essential.
dc.identifier.doi10.1007/s12020-024-03809-0
dc.identifier.endpage1309
dc.identifier.issn1355-008X
dc.identifier.issn1559-0100
dc.identifier.issue3en_US
dc.identifier.pmid38570387
dc.identifier.scopus2-s2.0-85189352019
dc.identifier.scopusqualityQ2
dc.identifier.startpage1300
dc.identifier.urihttps://doi.org/10.1007/s12020-024-03809-0
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14253
dc.identifier.volume85
dc.identifier.wosWOS:001196262300003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofEndocrine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMedullary thyroid carcinoma
dc.subjectDisease-free survival
dc.subjectExcellent response
dc.subjectPrognosis
dc.titleDisease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu